BioCAD

What BioCAD does

BioCAD (BIOCAD) is a Saint Petersburg, Russia-based, privately held full-cycle biotechnology company founded in 2001 that develops and manufactures biologic drugs across eight therapeutic areas, with primary focus on oncology biosimilars targeting blockbuster biologics whose patents have expired or are expiring. The company operates a vertically integrated platform spanning API synthesis through finished drug production, enabling end-to-end quality and supply-chain control for complex biologics. Its product portfolio includes the approved originator PD-1 inhibitor Forteca (prolgolimab), Daratumia — the world's first regulatory-approved daratumumab biosimilar referencing Johnson & Johnson's Darzalex (Russian Ministry of Health approval, August 2025) — and a pipeline candidate BCD-132 (divozilimab) for neuromyelitis optica spectrum disorder (NMOSD).

BioCAD commercializes products across more than 50 countries spanning Latin America, Southeast Asia, and the MENA region, leveraging both direct distribution and government procurement / tender channels, and benefiting from Russian domestic procurement preferences for domestically produced drugs and inclusion of its products on state VED and SSM reimbursement lists. The company reaches healthcare providers and oncology / autoimmune patients through scientific publication channels and specialist-facing portals, with clinical-trial and regulatory-approval milestones serving as primary credibility signals in lieu of traditional consumer marketing.

The business model is pharmaceutical product sales — predominantly biologics — sold through international distribution, government tenders, and reimbursement programs. Pricing is not publicly disclosed and is subject to country-specific procurement negotiation. A forward-looking strategic agreement with the Qatar Free Zones Authority (announced 2026-03-11) extends the model into manufacturing footprint expansion in the MENA region under Qatar's National Manufacturing Strategy 2024-30, targeting both import substitution and regional exports. Revenue is not disclosed in available sources.

Name

BioCAD

Legal name

BIOCAD

Website

https://biocadglobal.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

BioCAD is a Saint Petersburg-based, privately held full-cycle biotechnology company that develops and manufactures biosimilar and originator biologics, primarily oncology, targeting blockbuster patent-expired biologics across 50+ countries in Latin America, Southeast Asia, and MENA.

Ownership category

akta.pro rank

Product category

Biosimilar Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro industry

PRIMARYHLAAAHAG

Oncology Biosimilars

Healthcare & Life Sciences/Biotechnology & Biologics/Biosimilars & Biologic Generics

SECONDARYHLAIAJAH

Biologics & Biosimilars Distributors

Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling

SECONDARYHLAAAKAA

Biologic API/Drug Substance Manufacturing Services

Healthcare & Life Sciences/Biotechnology & Biologics/Biomanufacturing Services

SECONDARYCRAOAHAD

Specialty Pharmacy & Biologics Distribution

Consumer Products & Retail/Wholesale, Distribution & Category Management/Health, OTC & Pharmacy Wholesale Distribution

Keywords

• Biosimilar development
• Oncology biologics
• Pharmaceutical manufacturing
• Biotechnology research
• Autoimmune therapeutics

Headquarters

HQ city

Saint Petersburg

HQ country

Russia

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Biosimilar Drug Sales: Revenue generated from commercialization of biosimilar products targeting blockbuster oncology biologics whose patents have expired, marketed in over 50 countries across Latin America, Southeast Asia, and MENA regions
2. Originator Drug Sales: Revenue from approved originator PD-1 inhibitor products (prolgolimab/Forteca) alongside biosimilar portfolio

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

Core offering

BioCAD is a full-cycle biotechnology company that develops, manufactures, and commercializes biosimilar and originator biologic drugs, with vertically integrated capabilities spanning API synthesis through finished drug production. Its portfolio targets blockbuster oncology biologics with expired or expiring patents (notably the world's first approved daratumumab biosimilar, Daratumia) alongside an approved originator PD-1 inhibitor (Forteca/prolgolimab) and a pipeline candidate for NMOSD (BCD-132/divozilimab). Products span oncology, autoimmune, and infectious disease therapeutic areas and are marketed in over 50 countries across Latin America, Southeast Asia, and MENA.

Product overview

BioCAD is an innovative full-cycle biotechnology company based in Saint Petersburg, Russia. The company operates a vertically integrated manufacturing model and has systematically built a two-decade biosimilar franchise targeting blockbuster oncology biologics. The product portfolio includes approved originator drugs (PD-1 inhibitor Forteca/prolgolimab), world-first biosimilar approvals (Daratumia/daratumumab), and pipeline candidates (BCD-132 for NMOSD). Products span multiple therapeutic areas including oncology, autoimmune diseases, and infectious/viral diseases, with commercial presence in over 50 countries across Latin America, Southeast Asia, and the MENA region.

Differentiator

Problem solved

Functional benefit

Brands

• BCD-132: Divozilimab/BCD-132 - pipeline drug for neuromyelitis optica spectrum disorder (NMOSD) treatment
• Daratumia
• Forteca

Products and services

• Daratumia (daratumumab biosimilar) World's first regulatory-approved daratumumab biosimilar referencing Johnson & Johnson's Darzalex, approved by the Russian Ministry of Health in August 2025 for the treatment of multiple myeloma.
• Forteca (prolgolimab)
• BCD-132 (divozilimab) Pipeline drug in development by BioCAD for neuromyelitis optica spectrum disorder (NMOSD), expected to reshape the treatment landscape for this rare autoimmune condition.

Quantifiable outcome

• World's first regulatory approval for daratumumab biosimilar (Daratumia) in August 2025
• +1 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Qatar Free Zones AuthoritycoreStrategic or Co-development Partner · 11 March 2026Strategic agreement signed with Qatar Free Zones Authority to establish pharmaceutical manufacturing facilities in Qatari free zones. This partnership is part of Qatar's National Manufacturing Strategy 2024-30 which targets QR70.5 billion in sector value-added contribution. Qatar aims to reduce its $1.13 billion annual medicine import bill and establish itself as a regional export hub.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Celltrion: South Korea-based biosimilar specialist with a vertically integrated development and manufacturing model, commercializing biosimilars of blockbuster oncology and autoimmune biologics globally. Closely comparable to BioCAD in target molecule class, business model, and reliance on patent-cliff opportunities.
• Samsung Bioepis: Biosimilar-focused biotech backed by Samsung, developing and commercializing biosimilars in oncology, immunology, and ophthalmology across global markets. Highly comparable to BioCAD as a pure-play biosimilar developer with a multi-therapeutic-area commercial footprint.
• Biocon Biologics: Indian biosimilar developer with vertically integrated manufacturing and global commercial reach across oncology, autoimmune, and diabetes biologics. Directly comparable in being an emerging-market-headquartered biosimilar company competing with Western originator biologics internationally.
• Shanghai Henlius Biotech: Chinese biosimilar developer with an originator biologics pipeline, full-cycle manufacturing, and approvals across multiple geographies. Highly relevant given overlapping emerging-market positioning, biosimilar-plus-originator model, and global expansion ambitions similar to BioCAD.
• Mabxience: European biosimilar developer producing monoclonal antibody biosimilars targeting oncology and immunology reference products. Comparable to BioCAD as a multi-product biosimilar manufacturer operating in adjacent geographies with the same patent-cliff capture strategy.

Broad incumbents

• Amgen: Global large-cap biotech with both originator biologics (including PD-1 inhibitors) and a meaningful biosimilars franchise. Comparable to BioCAD as a vertically integrated developer/manufacturer of biologic oncology and autoimmune drugs with a broader portfolio.
• Pfizer (biosimilars portfolio): Global pharmaceutical major with a commercial biosimilars portfolio built through partnerships (e.g., legacy Hospira) targeting major oncology and autoimmune biologics. Comparable as a large multi-product biosimilar commercializer operating across the same regulatory markets.
• Dr. Reddy's Laboratories (biologics): Diversified Indian pharmaceutical company with a growing biologics and biosimilars franchise in oncology and autoimmune indications. Comparable to BioCAD as an emerging-market-headquartered, full-cycle biopharma targeting the same reference-product portfolio.

Emerging players

• Hetero Drugs: Indian pharmaceutical manufacturer with an expanding biosimilars portfolio across oncology and immunology, focused on emerging markets. Comparable to BioCAD in commercial focus on non-Western geographies and in pricing-sensitive tender channels.

Regional players

• Generium: Russian domestic biopharmaceutical company developing and commercializing biosimilars and originator biologics primarily within Russia and CIS. Most direct regional peer given shared Russian HQ, similar regulatory environment, and focus on domestic procurement for biosimilars targeting the same oncology/autoimmune indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/biocad_ltd
• Facebookfacebook.com/BIOCAD
• LinkedInlinkedin.com/company/biocad

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioCAD